A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
about
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndromeSystemic lupus erythematosusEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDiagnosis and treatment of deep-vein thrombosisManagement of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesSex differences in stroke: the contribution of coagulationRecommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answersGuidelines on oral anticoagulation with warfarin - fourth editionDirect oral anticoagulants in hypercoagulable states.Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort.Progression of antiphospholipid antibody syndrome to catastrophic antiphospholipid antibody syndrome acutely with cessation of antithrombotic therapy.Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis.The challenge of bleeding in antiphospholipid antibody-positive patients.Management of the antiphospholipid syndromeTherapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: A case report.Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and SafetyAntiphospholipid syndrome and the brain in pediatric and adult patientsGuidelines on oral anticoagulation (warfarin): third edition--2005 update.Idiopathic venous thromboembolism and thrombophiliaGuidelines for the treatment of antiphospholipid syndrome.Optimal duration of anticoagulation in patients with venous thromboembolism.Treatment of the antiphospholipid syndrome.Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.Thrombosis in systemic lupus erythematosus: a review articleCardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.Laboratory diagnosis and management challenges in the antiphospholipid syndrome.Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus.Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome.The antiphospholipid syndrome: still an enigmaLatest advances in connective tissue disorders.New developments in lupus-associated antiphospholipid syndrome.Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome.Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecologyThrombosis in systemic lupus erythematosus: risk and protection.Current management of antiphospholipid syndrome-related thrombosis.
P2860
Q24185949-111DCA89-7775-4BF9-A68B-54C6FA5EA652Q24543555-26654112-FBDD-4B16-AEE1-CBBCD86796F5Q24632951-8F2A5660-F942-489C-ADFA-EE090596031EQ24673847-41284396-0BA5-4683-B829-272CBBE7BA07Q26774815-500FE26F-2394-468C-892A-3812BC66B8C1Q27022768-CA487EC3-3859-43BF-9FD3-BD78A7D1140BQ28071739-1465CC7A-98C2-4567-82A4-DD4AB6340F14Q28196276-84624E2C-5562-4467-B7B7-D9B8F2F2164AQ28240666-384218E2-74C4-4ABA-9204-9078C8BE8462Q30275936-3EE8A41D-4BC0-4761-8DEA-06D0C6B37AF3Q33384874-BE646EAE-A15D-4EC7-B616-82F50DDB9AD3Q33401365-F8BF23F1-4FDA-4F0B-AEF8-E15DB54C60FFQ33406588-FB9F89FF-86C7-40A0-B9E2-CC332DDDFBB3Q33419972-B6E1CD70-92A4-4040-91C2-4ECF80372205Q33423034-6B2C47E4-565A-4568-9BD7-A1548FE48C4EQ33424085-B6A6A1AF-91F6-473A-B8E3-2492F2B13F6FQ33692770-F643376C-BF0A-4E34-B4EA-75E6508B7B72Q34307502-F486EA04-D7D3-4A98-8700-A952C25AF65CQ34484090-897AA4EF-25BE-4DB7-82AB-0874BC48EFB2Q34666620-C68FC134-9C34-4A8E-ACCE-B00176F5CDBFQ34821893-D71EB941-4DA6-4FC6-855C-0604ECC8DD48Q35210139-8CEC02F8-A00B-4DD7-84BA-D64F7CBC4689Q35308972-17673C5E-4893-4CBE-8574-694AD92C4968Q35621012-1367A254-5803-408F-A36B-1E767C0883E9Q35752584-B5E0200A-F1DA-4BB3-AADA-1782E553C658Q35925359-D9E2652E-401B-4356-A3E7-7873AC9C2BFEQ36147794-8D8D04E9-AB1A-4602-BEB6-80BC4B84B113Q36303250-479E1819-B55F-41B6-8E30-60FBE72487ADQ36458164-8EB345B6-58D5-4DCC-B937-C020D1EBA83DQ36461116-B90D8398-3FD4-4E39-98CD-C0D6DC875AB7Q36843689-49317692-7842-48E2-A9FC-0854778060EBQ36915667-BB8EE0A3-DDFD-4BC4-8DF2-8B4C3392D5E5Q36928593-467730C1-6823-41F3-B4B2-CC035E4EABAEQ37058776-7E877C73-FD87-4B3E-96A8-9F6C01819954Q37168035-AA351C08-1C73-4592-9B4F-8AB1BAEABA57Q37230504-76EDD2F8-01A3-42A5-B813-A108DDE476E8Q37473270-28CA96F1-BDFB-4996-9B42-58A1E8680C31Q37611378-B00562C2-436B-4ED2-8DB7-B55F3CD89F7CQ37642828-65B88343-514E-4366-BA49-23BBC2B99DCAQ37642830-C11C422B-35BD-4213-91A6-0FFEA58A33B3
P2860
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@ast
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@en
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@nl
type
label
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@ast
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@en
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@nl
prefLabel
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@ast
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@en
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@nl
P2093
P2860
P3181
P1476
A randomized clinical trial of ...... tiphospholipid syndrome (WAPS)
@en
P2093
A D'Angelo
M Berrettini
R Marchioli
P2860
P304
P3181
P356
10.1111/J.1538-7836.2005.01340.X
P407
P577
2005-05-01T00:00:00Z